Among them, we have developed a novel COVID-19 vaccine candidate based on the Modified Vaccinia Virus Ankara (MVA) poxvirus vector expressing the entire SARS-CoV-2 S protein (termed MVA-CoV2-S or MVA-S) (5). Here, PROS1 is linked to COVID-19.